<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02421289</url>
  </required_header>
  <id_info>
    <org_study_id>ID 05-56-13</org_study_id>
    <nct_id>NCT02421289</nct_id>
  </id_info>
  <brief_title>Influence of Cytochrome P2B6 on Efavirenz Dose in HIV-infected Thai Patients</brief_title>
  <official_title>Influence of Cytochrome P2B6 on Efavirenz Dose in HIV-infected Thai Patients in a Prospective Randomized Controlled Trial: a Proof-of-concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Genetic polymorphisms of cytochrome P450 2B6 (CYP2B6) are associated with lower rate of EFV&#xD;
      metabolism and lead to high exposure, as well as a higher risk of neuropsychiatric adverse&#xD;
      event especially homozygous variant CYP2B6 *6/*6. This trial was designed to compare the&#xD;
      proportion of patients who had undetectable HIV RNA at 24 weeks after ART initiation between&#xD;
      patient who did CYP 2B6 guided EFV dose and who did not.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV RNA</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric adverse events</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Cytochrome P-450 CYP2B6</condition>
  <condition>Efavirenz</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>CYP2B6 guided group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were assigned to perform CYP2B6 study before ART initiation. If CYP2B6 *6/*6 was found in CYP2B6 *6/*6, the patients will be initiated a low dose of 400 mg of efavirenz (2 tablets of 200 mg) with tenofovir 300 mg and lamivudine 300 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients were promptly ART initiation regardless CYP2B6 results. Treatments were efvirenz 600 mg, tenofovir 300 mg and lamivudine 300 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>There will be adjusted dose of efavirenz in CYP2B6 guide group</description>
    <arm_group_label>CYP2B6 guided group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>If the patients was diagnosed as hypersensitivity to EFV, they will receive boosted-PI instead.</description>
    <arm_group_label>CYP2B6 guided group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CYP450 2B6</intervention_name>
    <description>All patients will be monitored drug level which should be in therapeutic level.</description>
    <arm_group_label>CYP2B6 guided group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years old&#xD;
&#xD;
          -  Anti-HIV positive&#xD;
&#xD;
          -  Naïve to antiretroviral drugs&#xD;
&#xD;
          -  Meet the criteria to start ART to Thai National guidelines&#xD;
&#xD;
          -  Sign inform consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) &gt;25 kg/m²&#xD;
&#xD;
          -  Pregnant women or breastfeeding&#xD;
&#xD;
          -  Received drugs that may have interaction with EFV e.g. rifampicin, fluconazole&#xD;
             (400-800 mg), ergot alkaloid, midazolam, triazolam, ritonavir, carbamazepine,&#xD;
             phenytoin, phenobarbitone, St John's Wort&#xD;
&#xD;
          -  Having active opportunistic infections e.g. tuberculosis, cryptococcosis,&#xD;
             histoplasmosis, penicillosis&#xD;
&#xD;
          -  Hepatic dysfunction as indicated by:&#xD;
&#xD;
          -  Transaminases &gt;5-10 × the upper limit of normal&#xD;
&#xD;
          -  ALP &gt;5-10 × the upper limit of normal&#xD;
&#xD;
          -  Total bilirubin &gt;2.5-5 × the upper limit of normal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pansachee Damronglerd, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of medicine Ramathibodi Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pansachee Damronglerd, M.D.</last_name>
    <phone>+66 8515-6188</phone>
    <email>joh_pum@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sasisopin Kiertiburanakul, M.D., M.H.S.</last_name>
    <email>sasisopin@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of medicine Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pansachee Damronglerd, M.D.</last_name>
      <phone>+66 85-015-6188</phone>
      <email>joh_pum@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>April 8, 2015</study_first_submitted>
  <study_first_submitted_qc>April 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2015</study_first_posted>
  <last_update_submitted>August 2, 2015</last_update_submitted>
  <last_update_submitted_qc>August 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Pansachee DAMRONGLERD</investigator_full_name>
    <investigator_title>Ramathibodi Hospital</investigator_title>
  </responsible_party>
  <keyword>CYP2B6 polymorphism</keyword>
  <keyword>efavirenz</keyword>
  <keyword>Thai</keyword>
  <keyword>HIV-infected patient</keyword>
  <keyword>pharmacogenomic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 29, 2016</submitted>
    <returned>June 6, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

